#USA #New York #Securities Fraud #Rosen Law Firm #Capricor Therapeutics

Capricor Investors Encouraged to Join Class Action Lawsuit

Introduction

The Rosen Law Firm has alerted shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) regarding an unprecedented opportunity to lead a securities fraud lawsuit. This announcement specifically targets individuals who acquired Capricor securities between October 9, 2024, and July 10, 2025, and experienced losses exceeding $100,000.

Important Deadline

Investors are reminded that the deadline to apply as the lead plaintiff in this class action is September 15, 2025. Acting as a lead plaintiff enables individuals to represent the interests of other shareholders who suffered damages due to the alleged misleading statements made by Capricor's management during the aforementioned period.

No Costs Involved

A significant advantage for potential lead plaintiffs is that participating in the lawsuit entails no upfront costs. The Rosen Law Firm operates on a contingency fee basis, meaning any legal fees will be paid from any settlement or judgment obtained rather than from the plaintiffs' pockets.

How to Join the Class Action

To participate in this class action, shareholders can easily fill out a form via the Rosen Law website at Rosen Law Firm. Alternatively, interested parties can contact Phillip Kim at 866-767-3653 or reach out via email at [email protected] for further information.

Background on Capricor Therapeutics

Capricor Therapeutics is known for its pioneering work in developing therapies for heart conditions related to Duchenne muscular dystrophy (DMD). During the class period, Capricor made several claims regarding its lead cell therapy candidate drug, deramiocel, leading investors to believe this product would receive a Biologics License Application (BLA) approval from the U.S. Food and Drug Administration (FDA).

Allegations Against Capricor

The lawsuit presents allegations that Capricor's management issued statements that significantly inflated the company's stock price while omitting crucial safety and efficacy data from the Phase 2 HOPE-2 clinical trial of deramiocel. This misleading information allegedly caused investors to purchase Capricor shares at artificially inflated prices. When the truth emerged regarding the safety concerns, the share prices plummeted, resulting in significant financial losses for investors.

Why Choose Rosen Law Firm

Investors are encouraged to select seasoned legal counsel. The Rosen Law Firm has established itself as a leader in representing shareholders, known for successfully engaging in securities class actions. They have achieved significant settlements for their clients, including a historic case against a Chinese company, emphasizing their capability in navigating complex securities litigation. In 2019 alone, the firm secured over $438 million in recoveries for investors. Their reputation is bolstered by accolades from leading legal recognition platforms, such as Lawdragon and Super Lawyers.

Take Action Now

Shareholders of Capricor Therapeutics who experienced losses should act promptly. This lawsuit represents not only a chance for financial recovery but also an opportunity for investors to hold company executives accountable for their actions. By potentially joining this lawsuit, investors can contribute to a collective effort advocating for transparency and responsible corporate governance.

Follow for Updates

For regular updates and additional information, interested parties can follow the Rosen Law Firm on their social media channels, including LinkedIn, Twitter, and Facebook.

Conclusion

In conclusion, if you're among the many Capricor investors who have seen their investments decline, now is the time to take action. The upcoming deadline of September 15, 2025, provides a crucial window for you to join the class action and safeguard your rights as a shareholder. Remember, the right legal team could make a significant difference in not only the outcome of this case but also in the broader fight for investor rights.